Slocum Gordon & Co LLP Trims Stake in Kenvue Inc. (NYSE:KVUE)

Slocum Gordon & Co LLP cut its stake in Kenvue Inc. (NYSE:KVUE) by 0.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 257,813 shares of the company’s stock after selling 2,416 shares during the period. Kenvue accounts for 4.6% of Slocum Gordon & Co LLP’s investment portfolio, making the stock its 7th largest holding. Slocum Gordon & Co LLP’s holdings in Kenvue were worth $6,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Fulton Bank N.A. lifted its stake in Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock valued at $1,892,000 after buying an additional 465 shares during the period. SRS Capital Advisors Inc. lifted its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the period. Keystone Financial Group lifted its stake in Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company’s stock valued at $272,000 after buying an additional 578 shares during the period. First Horizon Advisors Inc. lifted its stake in Kenvue by 2.4% in the fourth quarter. First Horizon Advisors Inc. now owns 25,047 shares of the company’s stock valued at $535,000 after buying an additional 580 shares during the period. Finally, Transatlantique Private Wealth LLC lifted its stake in Kenvue by 5.7% in the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company’s stock valued at $228,000 after buying an additional 580 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KVUE has been the topic of several recent analyst reports. Barclays boosted their price target on Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, May 12th. Evercore ISI started coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 target price on the stock. Citigroup reaffirmed a “neutral” rating on shares of Kenvue in a research report on Friday, June 13th. Finally, UBS Group upped their target price on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $25.33.

Kenvue Trading Down 0.7%

NYSE KVUE opened at $21.21 on Wednesday. The firm has a market capitalization of $40.70 billion, a P/E ratio of 38.57, a PEG ratio of 3.32 and a beta of 0.98. The business has a fifty day simple moving average of $22.96 and a 200 day simple moving average of $22.39. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. Kenvue’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.87%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue’s payout ratio is currently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.